A study to assess the effect and safety of multiple subcutaneous doses of drisapersen in patients with Duchenne Disease

Phase 1

• Conditions: Duchenne Muscular Dystrophy; MedDRA version: 17.0Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disorders; Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]

• Registration Number: EUCTR2007-004819-54-SE
• Lead Sponsor: Prosensa Therapeutics BV

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01-31
• Last Update Posted: 19 February 2018

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Male
• Target Recruitment: 12

Inclusion Criteria

1. Boys aged between 5 and 16 years inclusive
2. Duchenne muscular dystrophy resulting from a mutation correctable by treatment with PRO051
3. Not ventilator dependent
4. Life expectancy of at least 6 months
5. No previous treatment with investigational medicinal treatment within 6 months prior to the study
6. Willing and able to adhere to the study visit schedule and other protocol requirements.
7. Written informed consent signed (by parent(s)/legal guardian and/or the patient, according to the local regulations).
Are the trial subjects under 18? yes
Number of subjects for this age range: 12
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Aberrant RNA splicing and/or aberrant response to PRO051, detected by in vitro PRO051 assay during screening.
2. Known presence of dystrophin in = 5% of fibres in a pre-study diagnostic muscle biopsy
3. Severe muscle abnormalities defined as increased signal intensity in >50% of the tibialis anterior muscle at MRI
4. FEV1 and/or FVC < 60% of predicted
5. Current or history of liver or renal disease
6. Acute illness within 4 weeks prior to treatment (Day 0) which may interfere with the measurements
7. Severe mental retardation which in the opinion of the investigator prohibits participation in this study
8. Severe cardiac myopathy which in the opinion of the investigator prohibits participation in this study
9. Need for mechanical ventilation
10. Creatinine concentration above 1.5 times the upper limit of normal (age corrected)
11. Serum ASAT and/or ALAT concentration(s) which suggest hepatic impairment
12. Use of anticoagulants, antithrombotics or antiplatelet agents
13. Subject has donated blood less than 90 days before the start of the study
14. Current or history of drug and/or alcohol abuse
15. Participation in another trial with an investigational product

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified